Wall Street Zen upgraded shares of AnaptysBio (NASDAQ:ANAB – Free Report) from a hold rating to a buy rating in a research note published on Saturday morning,Wall Street Zen reports.
ANAB has been the subject of several other research reports. TD Cowen decreased their price objective on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Wolfe Research reaffirmed an “outperform” rating and set a $78.00 target price on shares of AnaptysBio in a report on Monday, August 31st. Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of AnaptysBio in a research report on Tuesday. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.15.
Get Our Latest Analysis on ANAB
AnaptysBio Price Performance
AnaptysBio (NASDAQ:ANAB – Get Free Report) last posted its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 EPS for the quarter, beating the consensus estimate of ($0.46) by $5.57. The company had revenue of $27.49 million for the quarter, compared to analyst estimates of $14.06 million. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. During the same period in the prior year, the company earned ($1.30) earnings per share. As a group, equities analysts expect that AnaptysBio will post -1.48 EPS for the current year.
Institutional Investors Weigh In On AnaptysBio
A number of institutional investors have recently modified their holdings of the business. Tema ETFs LLC raised its holdings in AnaptysBio by 0.6% in the 2nd quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock worth $2,111,000 after purchasing an additional 201 shares during the period. Arizona State Retirement System increased its position in shares of AnaptysBio by 13.5% in the second quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock valued at $295,000 after buying an additional 518 shares in the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of AnaptysBio during the 2nd quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd raised its stake in shares of AnaptysBio by 940.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares during the period. Finally, Group One Trading LLC acquired a new position in shares of AnaptysBio during the 2nd quarter worth approximately $140,000.
About AnaptysBio
AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.
AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.
Featured Stories
- Five stocks we like better than AnaptysBio
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.
